ARCHIVES

New Treatment Approaches For A Variety Of Leukemias Described At ASH Meeting

This article is from The Cancer Letter archive.

Vol. 27 No. 1 | January 30, 2004

Download PDF Visit The Full Archive

Related Articles

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

March 25, 2011

Samuel Broder Plans To Leave Celera.

September 10, 2010

FDA Committee Oks AMSA for Group C List, Tables THC Request, Deadlocks On Estramustine NDA

July 3, 1981

Economic Analyses Of New Therapies Useful In Phase III Studies, Trialists Say

July 24, 2009

IOM Report Calls For FDA Authority Nutritional Supplement Health Claims

May 21, 2010

New Drug Reverses Damage To Liver In Stem Cell Transplant

September 27, 2002